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Abstract 
Objective: To report the long‑term safety and efficacy data of a third generation drug eluting stent (DES) with biode‑
gradable polymer in the complex patient population of diabetes mellitus after a follow‑up period of 5 years.
Background: After percutaneous coronary intervention patients with diabetes mellitus are under higher risk of 
death, restenosis and stent thrombosis (ST) compared to non‑diabetic patients.
Methods: In 126 centers worldwide 3067 patients were enrolled in the NOBORI 2 registry, 888 patients suffered from 
diabetes mellitus (DM), 213 of them (14%) being insulin dependent (IDDM). Five years follow‑up has been completed 
in this study.
Results: At 5 years, 89.3% of the patients were available for follow‑up. The reported target lesion failure (TLF) rates at 
5 years were 12.39% in DM group and 7.34% in non‑DM group; (p < 0.0001). In the DM group, the TLF rate in patients 
with IDDM was significantly higher than in the non‑IDDM subgroup (17.84 vs. 10.67%; p < 0.01). The rate of ST at 
5 years was not different among diabetic versus non‑diabetic patients or IDDM versus NIDDM. Only 10 (<0.4%) very 
late stent thrombotic events beyond 12 months occurred.
Conclusions: The Nobori DES performed well in patients with DM. As expected patients with DM, particularly those 
with IDDM, had worse outcomes. However, the very low rate of very late stent thrombosis in IDDM patients might 
have significant clinical value in the treatment of these patients.
Clinical trial registration ISRCTN81649913; http://www.controlled‑trials.com/isrctn/search.html?srch=81649913&sort=
3&dir=desc&max=10
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Background
Upon introduction, drug-eluting stents (DES) with their 
anti-restenotic properties clearly paved the new path 
in interventional cardiology and directed future device 
improvements for the clinical benefit of patients [1]. Ini-
tial enthusiasm was suppressed by long-term follow-up 
data that depicted some late side effects, later proven to 
be mainly related to the unwanted persistence of only ini-
tially necessary anti-proliferative drug or durable polymer 
carrier [2, 3]. Since then, numerous stent design enhance-
ments, known as “new stent generations” were marketed, 
succeeding not only to improve anti-restenotic efficacy 
but also to eliminate downsides of their predecessors [4]. 
Biodegradable polymer drug-eluting stents, were designed 
to provide polymer and drug free surroundings at the 
treatment site after early “vulnerable” restenotic period, 
thereby eliminating the potentially dangerous effects of 
persistent inflammatory stimulus [5]. With immediate 
efficacy evident, remote safety assumptions could not 
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be proven until results of very long-term outcomes were 
available [6]. Recent developments in poly- and mono-
mer technology demonstrated thromboresistance in 
blood-contact studies [7]. Potential biodegradable poly-
mer technology advantages over durable polymer drug-
eluting stents could be especially valuable in clinically 
complex patient subgroups, like patients with diabetes 
mellitus in whom results of percutaneous revasculariza-
tion are known to be worse compared with non-diabetic 
population [8, 9]. In patients with diabetes, the use of 
DES was associated with a significant reduction of target 
lesion restenosis without an increase in adverse events 
compared to bare metal stents and the use of a polymer-
free sotarolimus- and probutol eluting showed compa-
rable long-term efficacy and safety as second-generation 
durable polymer zotarolimus-eluting stents [10, 11]. As 
previously reported, Nobori Biolimus A9™ eluting stent 
(Terumo corporation, Tokyo, Japan) with biodegradable 
polymer technology was associated with relatively low 
rates of adverse events in diabetic subgroup and no stent 
thrombosis up to 2 years of follow-up in insulin-depend-
ent diabetes mellitus patients—a finding that demanded 
additional attention and investigation [12]. Therefore, the 
aim of this predefined sub-study was to further investigate 
long-term outcome up to 5  years of drug-eluting biode-
gradable polymer technology in high-risk population.
Methods
Patient population
Study design was previously reported in details [12, 13]. 
Briefly, the NOBORI 2 study was prospective, single-arm, 
multi-centre, worldwide registry designed to further vali-
date safety and efficacy of the Nobori stent in real-world 
patients. Only exclusion criterion was patient inability 
or unwillingness to provide informed consent to partici-
pate. The studied population consisted of 3067 patients 
enrolled between April 2008 and March 2009 in a total 
of 126 centers across Europe and Asia. Through data 
entry in the electronic case report form, based on prior 
diagnosis, patients were automatically assigned to pre-
defined analysis group of diabetic patients, and if they 
were on insulin therapy they were allocated to IDDM 
subgroup. Diabetes mellitus was diagnosed based on 
previous medical records of the patient and IDDM and 
NIDDM were differentiated based on presenting drug 
regimen of glucose lowering therapy. Age at diagnosis of 
DM was not recorded. No specific laboratory confirma-
tion was requested for confirmation of DM. The study 
was conducted according to the Declaration of Helsinki, 
ISO 14155 and respecting all country-specific regulatory 
requirements. The protocol was reviewed and approved 
by the ethics committee of each participating hospital 
and all patients gave written informed consent.
The Nobori Biolimus A9‑eluting stent
The Nobori DES system that was used in the study was 
described in detail previously [14] and comprises four 
components: (1) the bare metal stent platform; (2) the 
delivery catheter; (3) the biodegradable drug carrier (pol-
ylactic acid); (4) an anti-proliferative substance, Biolimus 
A9™. Contrary to other DES, the drug polymer matrix is 
applied only abluminally (toward the vessel wall).
Coronary stent procedure
Patients’ medication regimen, percutaneous access, 
lesion preparation, and stent implantations were per-
formed according to hospital routine practice. The treat-
ment of multiple target vessels and staged procedures 
were allowed. Peri-procedural dual antiplatelet and anti-
coagulation regimen were given at the discretion of the 
operators. A post-procedural electrocardiogram and the 
measurement of cardiac enzymes were recommended. 
Additional assessment of comorbidities was done using 
the Charlson comorbidity index [15].
Patient follow‑up
All patients were followed through hospital discharge 
and were scheduled for follow-up evaluations (hospital 
visit or telephone assessment) at 1, 6, and 12 months, and 
annually up to 5  years post-procedure. No mandatory 
angiographic follow-up was planned in this study. Dur-
ing the follow-up contacts, information about patients’ 
clinical condition, adverse events, hospitalizations, and 
changes to concomitant (cardiac and antiplatelet) medi-
cations were collected.
Study management
Data were collected through standardized electronic case 
report forms (KIKA Medical, Boston, MA, USA). Note-
worthy was to highlight a very high rate of data moni-
toring through online and on site check-ups. All major 
adverse cardiac events were assessed by independent 
clinical event committee. All baseline angiograms were 
analyzed by an independent core laboratory (CorExpert, 
Belgrade, Serbia).
Study endpoints
The primary endpoint was Academic Research Consor-
tium (ARC) defined, device oriented endpoint, a compos-
ite of cardiac death, myocardial infarction (MI) (Q-wave 
and non-Q-wave not clearly attributable to a non-target 
vessel) and target lesion revascularization (TLR), also 
known as target lesion failure (TLF). Secondary end-
points included: (1) TLF, (2) major adverse cardiac events 
(MACE) defined as cardiac death, MI, or any clinically 
driven target vessel revascularization (TVR), (3) death 
and MI, (4) TLR and TVR, (5) ARC defined, patient 
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oriented composite endpoint (POCE) that included any 
death, any MI and any coronary revascularization (6) 
stent thrombosis according to ARC definitions [16]. All 
outcomes were evaluated at 12 months and yearly there-
after for 5 years.
Statistical analysis
Data were presented as percentages and 95% confidence 
intervals for categorical variables, and means and stand-
ard deviations for continuous variables. All analyses were 
performed by an independent statistical office (SBD 
Analytics, Bekkevoort, Belgium) using SAS software, 
version 9.13 (SAS Institute Inc., Cary, NC, USA). All sta-
tistical tests were two-tailed with p < 0.05 considered to 
be statistically significant. Differences between IDDM 
and non-IDDM (NIDDM) patients were analyzed using 
Fisher’s exact test for binary variables, and Wilcoxon rank 
sum test for continuous variables.
Results
DM versus non‑DM
The final study population included 3067 patients, among 
which 888 patients suffered from DM, with 213 of them 
(14%) being insulin-dependent DM (IDDM). Patient 
characteristics, baseline, procedural and quantitative cor-
onary angiography analysis (QCA) were reported earlier 
and here are reported in Tables 1 and 2. BMI in patients 
with DM was significantly higher compared to patients 
without DM (28.9 vs. 27.2 kg/m2; p < 0.001). At 5 years, 
89.3% of patients were available for follow-up. TLF rate 
in diabetic patients was significantly higher from year 
1 (5.97 vs. 3.03%; p  <  0.0001) up to end of the 5  years 
follow-up period (12.39 vs. 7.34%; p  <  0.0001; Fig.  1; 
Table  3). As observed earlier this difference was driven 
mainly by cardiac death and TLR rates, while target 
vessel related MI rate did not differ in diabetic patients 
compared to non-diabetic (Figs. 2, 3). Rate of POCE was 
also significantly higher in DM group (22.86 vs. 13.72%; 
p  <  0.0001) with half of the accumulated 5  years differ-
ence being generated within 12 months (11.60 vs. 6.79%; 
p  <  0.0001; Fig.  4). Anginal status showed no differ-
ences between groups during study period with 87.87% 
of diabetic patients and 89.20% of non-diabetic patients 
being symptom free at the 5 years follow-up (p = 0.411; 
Table 3).      
IDDM versus NIDDM
BMI in patients with IDDM was significantly higher 
compared to patients with NIDDM (29.5 vs. 28.7 kg/m2; 
p < 0.001). Most of the difference in primary endpoints 
between non- and diabetic patients was driven by events 
occurring in IDDM patient subgroup (213 pts). Patients 
with IDDM had higher rate of TLF from 12  months 
(9.86 vs. 5.48%; p = 0.037) up to 5 years (17.84 vs. 10.67; 
Table 1 Baseline characteristics
PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CAD coronary artery disease, DM diabetes mellitus, IDDM insulin-dependent diabetes 













Age (years) (mean ± SD) 66.10 ± 10.13 66.56 ± 10.13 0.740 66.45 ± 10.12 63.53 ± 11.16 <0.001
Male sex 67.14 76.93 0.065 72.30 80.27 <0.001
Previous PCI 36.15 33.13 0.455 33.86 31.40 0.199
Previous CABG 13.62 8.06 0.021 9.40 8.57 0.481
Previous MI 33.01 32.83 1.000 32.87 33.27 0.864
Current smoker 16.94 18.12 0.826 17.85 28.66 <0.001
Previous smoker 31.15 37.73 0.115 36.20 33.97 0.269
Hypercholesterolemia 78.57 76.30 0.573 76.85 68.65 <0.001
Hypertension 86.38 79.70 0.034 81.31 64.03 <0.001
Family history of CAD 29.27 29.65 1.000 29.56 38.93 <0.001
Peripheral vascular disease 15.08 10.46 0.098 11.57 4.61 <0.001
Congestive heart failure 12.12 4.60 <0.001 6.39 2.89 <0.001
Charlson comorbidity index (mean ± SD) 2.61 ± 1.67 2.10 ± 1.27 <0.001 2.21 ± 1.39 0.84 ± 0.91 <0.001
Baseline anginal status
 Stable angina 46.23 44.66 0.693 45.03 46.12 0.603
 Unstable angina 33.49 38.87 0.168 37.58 39.74 0.271
 Silent ischemia 20.28 16.47 0.213 17.38 14.13 0.026
 ACS 50.70 52.44 0.694 52.03 54.06 0.318
 STEMI in ACS 8.3 16.1 0.042 14.3 15.5 0.59
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p  <  0.01; Fig.  5). Contrasting the findings between DM 
and non-DM, insulin dependence did not significantly 
increase the rate of TLR among DM patients not at 1 
(5.63 vs. 3.11%; p = 0.09) or at the end of 5 years period 
(8.45 vs. 5.04%; p = 0.09). Rate of cardiac death and tar-
get vessel MI was not significantly increased in the IDDM 
group at 5 years or at any follow-up point, while rate of 
POCE showed early increment that persisted through the 
study period (Figs. 6, 7, 8).
Stent thrombosis
Rate of study ST (definite and probable according to 
the ARC definitions) was not different among diabetic 
versus non-diabetic patients or IDDM versus NIDDM 
at any time point (Table  4). Most of the ST occurred 
within 30 days of implantation (19/34 ST; 55%) and only 
10 (<0.4%) very late stent thrombotic events beyond 
12 months were observed in whole study population.
Antiplatelet therapy
Mean loading dose of Clopidogrel was 415  mg in DM 
patients versus 442  mg in non-DM patients (p  =  0.02) 
and 412 mg in IDDM patients versus 416 mg in NIDDM 
patients (p = 0.84). Dual antiplatelet therapy duration at 
1 year was 77.4% in DM patients versus 71.4% in non-DM 
patients (p = 0.01), while for IDDM patients it was 77.3% 
compared to 77.4% in NIDDM patients (P = 1).
Discussion
Present study shows long-term outcomes of biodegrad-
able polymer drug eluting stent (BP-DES) treatment in 
highly unselected set of patients, especially in high-risk 
subgroup of patients with DM. Main findings of our 
analysis are: (1) Patients with DM have worse outcomes 
than non-diabetic patients with significantly higher rates 
of TLF, cardiac death and POCE throughout the whole 
study period; (2) Presence of insulin-dependent therapy 
among diabetic patients relates with more repeat revas-
cularization events but not in higher rates of harder 
clinical endpoints, cardiac death and target vessel MI; (3) 
Cumulative rate of ST in whole population for the 5 years 
period was relatively low, especially rate of very-late ST; 
(4) Rate of stent thrombosis was similar between patients 
with and without DM, and insulin therapy did not 
increase the incidence of thrombotic events; Overall, our 
results confirm findings of previous reports that patients 
with DM, and especially those with IDDM, are at higher 
risk of adverse events following PCI [17]. Study results 
also demonstrated the overall very good performance of 
the BP-DES system in this high-risk patient population.
Table 2 Procedural and QCA results














Nr of diseased vessels 1.81 ± 0.79 1.83 ± 0.78 0.701 1.83 ± 0.78 1.69 ± 0.76 <0.001
Nr of treated vessels 1.30 ± 0.52 1.28 ± 053 0.516 1.29 ± 0.53 1.23 ± 0.48 0.008
Nr of lesions detected 2.15 ± 1.18 2.19 ± 1.16 0.555 2.18 ± 1.17 1.96 ± 1.11 <0.001
Nr of lesions treated 1.51 ± 0.87 1.52 ± 0.81 0.977 1.52 ± 0.80 1.43 ± 0.76 <0.001
Nr of implanted stents per 
paent
1.73 ± 1.06 1.80 ± 1.17 0.694 1.79 ± 1.14 1.71 ± 1.07 0.122
Nr of implanted stents per 
lesion
1.15 ± 0.56 1.18 ± 0.58 0.470 1.18 ± 0.58 1.20 ± 0.57 0.182
Baseline QCA pre- and 
post-procedure
N-lesion = 321 N-lesion = 1028 N-lesion = 1349 N-lesion = 3114
RVD pre-procedure (mm) 2.55 ± 0.64 2.57 ± 0.58 0.581 2.57 ± 0.59 2.63 ± 0.57 0.001
DS pre-procedure (%) 67.7 ± 17.3 67.8 ± 16.7 0.799 67.8 ± 16.8 68.3 ± 17.8 0.356
Lesion length (mm) 15.48 ± 8.56 14.82 ± 8.80 0.151 14.97 ± 8.75 15.86 ± 9.92 0.017
MLD post-procedure—in-
stent (mm)
2.44 ± 0.49 2.48 ± 0.47 0.619 2.47 ± 0.47 2.52 ± 0.47 0.004
DS post-procedure—in-
stent (%)
13.1 ± 7.4 12.8 ± 6.7 0.827 12.9 ± 6.9 13.1 ± 7.1 0.388
Acute gain—in-stent (mm) 1.62 ± 0.59 1.65 ± 0.56 0.677 1.64 ± 0.57 1.69 ± 0.58 0.025
QCA qualitative comparative analysis, SD standard deviation, N number of patients, DM diabetes mellitus, IDDM insulin-dependent diabetes mellitus, RVD reference 
vessel diameter, DS diameter stenosis, MLD minimal luminal diameter, Nr number, vs versus
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Fig. 1 Primary endpoint: TLF incidence. TLF target lesion failure
Table 3 Clinical outcomes at 1–5 years of follow-up
DM diabetes mellitus, NDM patient without DM, IDDM insulin-dependent diabetes mellitus, N number of patients, MI myocardial infarction, TLR target lesion 
revascularization, TVR target vessel revascularization, MACE major adverse cardiovascular events, POCE patient-oriented composite endpoint, TLF target lesion failure, 
vs versus
% 12 months 2 years 3 years 4 years 5 years
DM NDM P DM NDM P DM NDM P DM NDM P DM NDM P
Cardiac death 1.91 0.92 0.028 3.60 1.42 <.000 4.73 1.76 <.000 5.29 2.34 <.000 5.97 2.66 <.000
Non‑cardiac death 0.90 0.41 0.111 2.14 1.10 0.040 3.38 1.7 0.006 4.84 2.11 <.000 5.41 2.57 <.000
Target vessel MI 1.80 1.33 0.324 2.82 1.88 0.130 3.15 2.16 0.121 3.49 2.25 0.060 3.83 2.52 0.057
TLR 3.49 1.65 0.003 4.39 2.71 0.023 4.73 3.12 0.032 5.41 3.63 0.028 5.86 4.08 0.036
TVR 4.62 2.57 0.004 2.14 1.65 0.369 7.21 5.05 0.025 8.33 5.78 0.012 2.82 2.25 0.365
MACE 7.8 4.5 <.000 11.2 6.4 <.000 13.1 7.9 <.000 14.5 9.0 <.000 15.8 10.1 <.000
POCE 11.60 6.79 <.000 15.2 8.44 <.000 18.24 10.6 <.000 21.06 12.25 <.000 22.86 13.72 <.000
TLF 5.97 3.03 <.000 8.67 4.77 <.000 10.25 5.6 <.000 11.15 6.52 <.000 12.39 7.34 <.000
Anginal status
 Stable angina 10.54 9.97 0.680 11.07 9.71 0.292 11.4 9.76 0.255 10.41 9.50 0.590 10.57 9.69 0.602
 Unstable angina 0.86 1.08 0.684 1.03 0.91 0.827 0.15 0.71 0.127 0.41 0.96 0.373 1.37 0.96 0.454
 Silent ischemia 0.74 1.52 0.102 0.90 1.42 0.346 1.06 1.54 0.440 0.41 0.48 1 0.20 0.15 1
 No angina 87.87 87.43 0.802 87.00 87.96 0.519 87.39 87.99 0.674 88.78 89.06 0.865 87.87 89.20 0.411
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Fig. 2 Secondary endpoint: survival from cardiac death
Fig. 3 Secondary endpoint: survival from TLR. TLR target lesion revascularization
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Fig. 4 Survival from patient oriented composite endpoints. POCE patient oriented composite endpoints
Fig. 5 Survival from TLF in non‑IDDM versus IDDM. TLR target lesion failure
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Fig. 6 Survival from cardiac death in IDDM versus non‑IDDM
Fig. 7 Survival from myocardial infarction in IDDM versus non‑IDDM
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Clinical outcomes of Nobori stent implantation have 
been demonstrated in previous studies [12–14, 18]. This 
is the first study with a 5  years follow up specifically 
assessing its long-term performance in unselected group 
of patients with high-risk features for adverse prognosis 
like DM, especially IDDM.
Patients with DM compared to non-DM patients have 
less favorable outcomes in general, especially with per-
cutaneous revascularization and with longer duration 
of follow-up [17]. Although the magnitude of reste-
nosis reduction achieved with earlier DES platforms 
was impressive compared to BMS in most of the early 
randomized trials, this effect was not less evident in real 
world practice among patients with DM [19]. Differen-
tial clinical responses  in patients with and without DM 
was documented even with new stent platforms high-
lighting the need for further opportunity to improve 
the treatment of CAD in patients with DM, particu-
larly in those treated with insulin [20]. Meta-analyses 
showed that DES, compared to bare metal stents, were 
efficacious without compromising safety and assumed a 
potential highest benefit for patients with diabetes mel-
litus after treatment with everolimus eluting stents [11]. 
As expected, patients with DM had more adverse events 
Fig. 8 Survival from POCE in IDDM versus non‑IDDM















30 days (early ST) 0.90% (8/888) 0.50% (11/2179) 0.2106 0.94% (2/213) 0.89% (6/675) 1
6 months 0.90% (8/888) 0.64% (14/2179) 0.480 0.94% (2/213) 0.89% (6/675) 1
12 months (late ST) 0.90% (8/888) 0.73% (16/2.179) 0.653 0.94% (2/213) 0.89% (6/675) 1
2 years 1.01% (9/888) 0.78% (17/2.179) 0.519 0.94% (2/213) 1.04% (7/675) 1
3 years 1.13% (10/888) 0.92% (20/2.179) 0.685 0.94% (2/213) 1.19% (8/675) 1
4 years 1.35% (12/888) 0.92% (20/2.179) 0.326 1.41% (3/213) 1.33% (9/675) 1
5 years 1.35% (12/888) 1.01% (22/2.179) 0.447 1.41% (3/213) 1.33% (9/675) 1
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in our analysis with higher TLR (5.8 vs. 4.1; p = 0.036), 
cardiac death (5.97 vs. 2.66%; p  <  0.001) and composite 
endpoints MACE (15.8 vs. 10.1%; p < 0.001) and POCE 
(22.9 vs. 13.72%; p < 0.001).
Since results from long-term follow-up in diabetic 
patients treated with available biodegradable polymer 
stent platforms are lacking, it is justifiable to compare 
our findings to results of earlier DES platforms and 
durable polymer DES generations, demonstrating over-
all good performance of Nobori Biolimus A9 stent with 
low event rates in patients with or without DM (Table 4) 
[21–30]. Rate of MACE in DM group was lower than 
previously reported (15.8 vs. 17.0–40.5%) while rates of 
TLR (5.9 vs. 4.6–18.3%) cardiac death (5.9 vs. 2.4–15%) 
and MI (3.8 vs. 1.3–13.6%) also compared favorably with 
historical reports residing in lower edge of rates ranges. 
Very recently, the 5-years follow-up data of the diabetes 
subgroup of the ISAR Test 5 trial showed non-inferior-
ity of a polymer-free sirolimus- and probucol-eluting 
stent compared to a second-generation durable poly-
mer zotarolimus-eluting stent. Nevertheless, the rate of 
MACE, TLR, cardiac, and MI was higher in both arms 
of this study compared to our results. If these findings 
assume a superiority of BP-DES needs further investiga-
tion [10].
Long-term efficacy and safety of DES was subject of 
considerable debate with reports mainly from large-
scale registries conflicting the excellent results of ran-
domized trials focusing on immediate efficacy with 
shorter clinical evaluation periods. SCAAR study group 
drew attention of scientific community with results 
from large-scale registry showing increase in mortality 
in patients with DES compared with BMS before (HR 
1.20) and after 6 months up to 3 years period (HR 1.32). 
High or prolonged antiproliferative drug delivery and 
persistent inflammatory propensities of durable poly-
mers were heavily related with inadequate vessel heal-
ing, predisposing treated vessels to late adverse events 
[31–33]. Conceptually, design of biodegradable poly-
mer stents were attractive solution since ultimately their 
long-term effects resemble BMS-like interaction with 
the vessel wall with less inflammatory stimulus. Recent 
reports showed that biodegradable polymers offer clear 
academic but equivocal clinical advantage. In large com-
parison, meta-analysis of 20.005 pts, treatment with BP-
DES significantly reduced LLL and LST rates, without 
clear benefits on harder endpoints compared to durable 
polymer (DP)-DES [6]. High-risk population like STEMI 
patients also could benefit from BP-DES. In 497 patients 
with STEMI at 4 years, MACE was significantly reduced 
following treatment with BP-DES (hazard ratio [HR] 
0.59, 95% CI 0.39–0.90; p = 0.01). Effect was driven by 
reduced TLR (HR 0.54, 95% CI 0.30–0.98; p  =  0.04). 
Trends were also seen for cardiac death or MI (HR 0.63, 
95% CI 0.37–1.05; p  =  0.07) and definite or probable 
stent thrombosis (3.6 vs. 7.1%; HR 0.49, 95% CI 0.22–
1.11; p  =  0.09). Similar conclusions were drawn from 
pooled individual patient-level data from 3 randomized 
clinical trials [34] comparing biodegradable polymer 
DES with durable polymer (DP) DES. Clinical outcomes 
at 4 years were assessed. Out of 1094 patients with dia-
betes included in the analysis, 657 received BP-DES and 
437 DP-DES. At 4  years, the incidence of the primary 
end point was similar with BP-DES versus DP-DES (HR 
0.95, 95% CI 0.74–1.21, P =  0.67). But, rate of definite 
or probable stent thrombosis was significantly reduced 
in patients treated with BP-DES (HR 0.52, 95% CI 0.28–
0.96, P = 0.04), and this difference was driven by signifi-
cantly lower stent thrombosis rate with BP-DES after 1 
and up to 4 years (HR 0.15, 95% CI 0.03–0.70, P = 0.02) 
eliminating the fear from late “catch-up” phenomenon 
with biodegradable polymers [35]. And indeed, serial 
optical coherence studies at 6, 12 and 24  months from 
implantation of BP-DES, Nobori Biolimus stent, did 
show that favorable features like, small gradual increase 
in neointimal thickness, with a nonsignificant decrease 
in the lumen area, lowering frequency of uncovered 
struts to almost none with very low percentage of 
detectable thrombi and peri-strut low-intensity area, 
could explain such low thrombotic risk beyond 1  year 
period. In addition, atherogenic neointima was not 
observed in the event-free OCT cohort [36]. When com-
pared to Sirolimus eluting stent (SES) and BMS, BP-DES 
lies somewhere in-between according to recent OCT 
analysis. Biodegradable polymer Biolimus eluting stent 
showed a favorable coronary arterial response compared 
with SES, but different response with BMS at 5 years fol-
low-up. The observed frequency of in-stent neoathero-
sclerosis within BP-DES was similar to BMS and tented 
to be lower than SES [37]. These obvious pathological 
and angiographically described potential advantages 
could explain low rates of ST occurring in 1.01, 1.35 and 
1.41% in non-DM, DM and IDDM patients respectively 
up to 5 years with 24 (70%) occurring within 12 months. 
Rate of ST compared favorably to historical reports 
(0.8–10.2%). Results of trials with long term follow up 
after drug eluting stent implantation in patient with dia-
betes mellitus are summarized in Table 5.
Study limitations
Our study has several limitations. First, the diagnosis of 
DM was performed only on the bases of patients medi-
cal history without any confirmatory tests, potentially 
leading to lower incidence. Additionally, the diagnosis 
of diabetes was self reported and uncontrolled. Thus, the 
“non-DM” group could contain patients with unreported 
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diabetes. Furthermore, NOBORI 2 is the non-rand-
omized registry and the comparison with other DES is 
limited to historical data. Under-reporting of adverse 
events during follow-up is also possible. However, this 
registry is based on close online and on-site source data 
monitoring and relatively high follow-up compliance 
rate, we can assume that adverse event non-reporting can 
be considered as a matter of exception.
Conclusion
This analysis of the 5-years outcomes suggests that the 
Nobori biodegradable polymer DES is a suitable treat-
ment option for overall but especially for high risk popu-
lation subset like DM patients with clinical outcomes and 
safety profile that compare favourably to different DES 
platforms.
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